Skip to main content

Cantargia’s Immuno-oncology Project CAN04 Shows Promise in Additional Cancer Forms

Cantargia AB today announces that the company has generated novel data showing high levels of interleukin-1 receptor accessory protein (IL1RAP) in tumors from patients with liver cancer, esophageal cancer as well as head and neck cancer. In addition, Cantargia’s lead candidate CAN04, an IL1RAP binding antibody in clinical trials, showed potent antitumor activity in in vitro models of these cancer forms.
http://www.prnewswire.co.uk/news-releases/cantargias-immuno-oncology-project-can04-shows-promise-in-additional-cancer-forms-682771891.html

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino